Vaccine Excipient Suppliers in India: What
Manufacturers Need to Know in 2025
India manufactures more than 60 percent of the world's vaccines. From BCG and polio
vaccines to COVID-19 vaccines and now mRNA products in development, Indian vaccine
manufacturers supply to national immunization programs across more than 150 countries.
Behind every successful vaccine is a carefully designed formulation. And that formulation
depends on a range of excipients that most people outside the industry never think about.
Excipients stabilize the vaccine antigen, preserve potency through the cold chain, help the
immune system respond appropriately, and keep the product safe for injection.
Finding reliable vaccine excipient suppliers in India with the right quality documentation and
regulatory compliance is a real challenge. This guide breaks down everything formulators,
procurement teams, and R&D scientists need to know.
What Are Vaccine Excipients?
Vaccine excipients are all the non-antigenic components in a vaccine formulation. They
include stabilizers, adjuvants, buffers, tonicity agents, preservatives, surfactants, and residual
manufacturing materials.
Unlike excipients in conventional injectables, vaccine excipients have some unique
characteristics:
? They must be compatible with biological antigens (proteins, polysaccharides, viral
particles, mRNA)
? They must maintain vaccine potency through thermal stress, freeze-thaw cycles, and
long-term storage
? Some, like adjuvants, directly influence the immune response
? They must have extremely low endotoxin levels to avoid triggering non-specific
immune reactions
? All components must be declared in the product's regulatory submission (IND, NDA,
BLA, WHO PQ dossier)
Types of Vaccine Excipients and Their Functions
Stabilizers
Stabilizers protect the vaccine antigen from degradation. In lyophilized (freeze-dried)
vaccines, stabilizers preserve the biological activity of the antigen during the drying and
reconstitution process.
Common stabilizers used in vaccines include:
? Sucrose and trehalose (disaccharide cryoprotectants widely used in lyophilized
biologics)
? Human serum albumin (HSA) used at low concentrations in some live virus vaccines
? Gelatin (used historically in MMR and varicella vaccines, though being phased out in
some products)
? Pharmaceutical-grade collagen peptides and low-endotoxin gelatin alternatives
Adjuvants
Adjuvants enhance the immune response to the vaccine antigen, allowing lower antigen doses
to be used and improving protection. Common adjuvants include:
? Aluminum hydroxide (Alhydrogel) and aluminum phosphate for traditional vaccines
? AS04, MF59, and AS01B for more advanced vaccine platforms
? CpG oligonucleotides for hepatitis B and certain next-generation vaccines
Adjuvant excipient quality is particularly critical because adjuvants are designed to activate
the immune system, and any quality deviation can affect both safety and efficacy.
Buffers
Maintaining a stable pH is essential for vaccine integrity. Common buffers in vaccine
formulations include:
? Phosphate buffered saline (PBS) for many conventional vaccines
? Histidine buffer for protein subunit vaccines and mRNA lipid nanoparticle
formulations
? Tris buffer for certain gene therapy and vaccine applications
Tonicity Agents
Sodium chloride is the most common tonicity agent used in vaccine formulations to achieve
isotonic conditions. In some products, mannitol or sorbitol may be used in combination.
Surfactants
Polysorbate 20 and polysorbate 80 are widely used in vaccine formulations to stabilize
protein antigens and prevent aggregation. In mRNA vaccine formulations using lipid
nanoparticles (LNPs), PEGylated lipids and other surfactant components are critical to the
delivery system.
Preservatives
Multi-dose vaccine vials require preservatives to prevent microbial contamination.
Thiomersal (thimerosal) is still used in some WHO-recommended multi-dose vaccine
formats, particularly in developing country programs. Phenol and 2-phenoxyethanol are used
in others.
pH Modifiers
Sodium hydroxide and hydrochloric acid are used to adjust and fine-tune pH during vaccine
manufacturing. While not functional excipients in the traditional sense, their pharmaceutical
grade is important.
The Regulatory Landscape for Vaccine Excipients in India
Vaccine manufacturing in India is regulated by CDSCO (Central Drugs Standard Control
Organisation) under the Ministry of Health. For vaccine products intended for international
markets or WHO prequalification, additional requirements apply.
Domestic Requirements
The Drugs and Cosmetics Act and its associated schedules govern all pharmaceutical and
vaccine manufacturing in India. Schedule M lays out GMP requirements for biological
products including vaccines.
WHO Prequalification
Many Indian vaccine manufacturers export to UNICEF and UN agencies under WHO
prequalification. All excipients used in a WHO PQ product must be listed in the dossier with
specifications, CoAs, and supplier information.
USFDA Biologics License Application (BLA)
For US market access, each excipient in a vaccine must be documented with pharmacopoeial
references or a master file. USFDA inspects vaccine manufacturing facilities and can raise
queries about excipient sourcing and qualification.
EMA (European Medicines Agency)
European market requirements demand that excipients meet EP specifications and that
manufacturers maintain a complete supply chain traceability system.
Key Challenges for Indian Vaccine Manufacturers in
Sourcing Excipients
Import Dependency
Despite India's vaccine manufacturing scale, many specialty vaccine excipients including
pharmaceutical-grade gelatin alternatives, low-endotoxin sucrose for lyophilization, and
adjuvant components are still primarily imported. European and Japanese manufacturers
dominate supply of these specialty ingredients.
mRNA Vaccine Excipients
The emergence of mRNA vaccines has introduced new excipient categories that are not yet
widely manufactured in India, including ionizable lipids, PEG-lipids, and DSPC
(distearoylphosphatidylcholine). Supply of these components for India's mRNA vaccine
development programs depends almost entirely on international suppliers.
Documentation Complexity
Vaccine regulatory submissions require comprehensive excipient documentation including
certificates of origin, GMP certificates, detailed specifications, and pharmacopoeial
compliance certificates. Many smaller Indian excipient suppliers are not equipped to provide
the full documentation package required for WHO PQ or USFDA filings.
Cold Chain Compatibility Testing
Excipients in vaccines must be validated not just for chemical compatibility with the antigen
but also for performance under the specific cold chain conditions of the target markets. This
requires specialized stability testing capabilities.
What to Look for in a Vaccine Excipient Supplier in India
When qualifying a vaccine excipient supplier, your checklist should include:
1. Pharmacopoeial monograph compliance (USP, EP, JP as applicable)
2. Batch-specific endotoxin testing reports
3. GMP certification of the manufacturing site
4. Ability to supply a completed Excipient Information Package (EIP)
5. Regulatory support including DMF availability or ability to support dossier
requirements
6. Stability data under relevant storage conditions
7. Track record of supply to vaccine manufacturers
Clyzo (clyzo.com) specifically maintains a category for vaccine-grade excipients with low
endotoxin pharma-grade products designed for vaccine formulation and production. The
platform also provides access to regulatory documentation directly, which is a major
advantage for manufacturers working under tight dossier timelines.
Emerging Trends in Vaccine Excipient Use in India
Shift to Preservative-Free Multi-Dose Formats
There is a global push to eliminate thiomersal from vaccines. This is driving development of
new preservative systems and container closure innovations that reduce the need for
traditional preservatives.
Next-Generation Adjuvants
India's vaccine R&D pipeline includes candidates using novel adjuvant systems. Sourcing
high-purity adjuvant components domestically is still limited but growing.
Collagen Peptides and Gelatin Alternatives
Traditional gelatin-based stabilizers are under scrutiny due to religious, ethical, and
allergenicity concerns. Plant-derived and recombinant alternatives are being explored.
Products like VACCIPRO (a collagen peptide for vaccine use) are examples of innovation in
this space.
Lipid Nanoparticle Excipients
As Indian companies progress in mRNA vaccine development, demand for pharmaceutical-
grade ionizable lipids, helper lipids, PEG-lipids, and cholesterol meeting injectable
specifications will increase. This is currently one of the largest supply chain gaps in India's
vaccine ecosystem.
Frequently Asked Questions
What excipients are used in COVID-19 vaccines manufactured in India? The COVID-19
vaccines developed and manufactured in India, such as Covaxin (inactivated virus), use
excipients including aluminum hydroxide gel as adjuvant, phosphate buffers, sodium
chloride, and beta-propiolactone in the inactivation process. mRNA vaccines use lipid
nanoparticle components, PEG-lipids, and histidine buffers.
Is low-endotoxin sucrose available in India for vaccine lyophilization? Yes.
Pharmaceutical-grade, low-endotoxin sucrose meeting USP and EP specifications is available
through specialty excipient platforms like Clyzo (clyzo.com).
What is the role of polysorbate 80 in vaccine formulations? Polysorbate 80 is a surfactant
that prevents protein antigen aggregation, stabilizes emulsions, and in lipid nanoparticle-
based vaccines, supports the structural integrity of the delivery system.
How can Indian vaccine manufacturers improve excipient documentation for WHO PQ
submissions? Working with suppliers that provide full Excipient Information Packages
(EIPs), batch-specific CoAs with endotoxin data, and GMP certificates significantly
simplifies the dossier process. Platforms like Clyzo (clyzo.com) are built specifically to
provide this documentation alongside the product.
Published on clyzo.com | Vaccine excipient solutions for India's pharmaceutical and biotech
industry
